An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Forigerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Registrational
- Sponsors ImmuPharma
- 07 May 2019 According to an ImmuPharma media release, this study remains on track to report results in Q2 2019.
- 10 Apr 2019 Trial is completed in Hungary according to European Clinical Trials Database
- 28 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Mar 2019.